Allarity Therapeutics (DB:C6D0) - Aktienkurs, Nachrichten und Analyse

Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

C6D0 Aktienübersicht

A clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology.

Über das Unternehmen

C6D0 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Belohnungen

Risikoanalyse

Hat keine nennenswerte Marktkapitalisierung (€3M)

Erzielt weniger als 1 Million USD an Einnahmen ($0)

Negatives Eigenkapital

Die Aktionäre wurden im vergangenen Jahr erheblich verwässert

+ 2 mehr Risiken

Allarity Therapeutics, Inc. Wettbewerber

bioXXmed

XTRA:T5O

€2.5m

NeuBase Therapeutics

DB:O7P

€1.3m

Deutsche Biotech Innovativ

MUN:DBI

€1.1m

co.don

XTRA:CNW

€6.5m

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for Allarity Therapeutics
Historical stock prices
Current Share Price	US$1.73
52 Week High	US$72.10
52 Week Low	US$1.73
Beta	0
1 Month Change	0%
3 Month Change	-15.67%
1 Year Change	-97.01%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-99.59%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	C6D0	DE Biotechs	DE Markt
7D	0%	1.4%	0.4%
1Y	-97.0%	-21.0%	4.4%

Rendite im Vergleich zur Industrie: C6D0 unter dem Niveau der Branche German Biotechs, die im vergangenen Jahr eine Rendite von -36.9% erzielte.

Rendite vs. Markt: C6D0 hinter dem Markt German zurück, der im vergangenen Jahr eine Rendite von 8.6 erzielte.

Preisvolatilität

Is C6D0's price volatile compared to industry and market?
C6D0 volatility
C6D0 Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.2%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	10.3%
10% least volatile stocks in DE Market	2.6%

Stabiler Aktienkurs: C6D0Der Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: Unzureichende Daten, um die Volatilitätsveränderung von C6D0 im vergangenen Jahr zu bestimmen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2004	13	James Cullem	www.allarity.com

Allarity Therapeutics, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Allarity Therapeutics im Vergleich zum Marktanteil des Unternehmens?
C6D0 grundlegende Statistiken
Marktanteil	€3.16m
Gewinn(TTM)	-€18.14m
Umsatz(TTM)	n/a

0.0x

Kurs-Umsatz-Verhältnis

-0.2x

Kurs-Gewinn-Verhältnis

Ist C6D0 zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
C6D0 Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$0
Kosten der Einnahmen	US$0
Bruttogewinn	US$0
Sonstige Ausgaben	US$19.76m
Umsatz	-US$19.75m

Zuletzt gemeldete Gewinne

Mar 31, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-1.03
Bruttomarge	0.00%
Nettogewinnspanne	0.00%
Schulden/Eigenkapital-Verhältnis	-1,120.1%

Wie hat sich C6D0 auf lange Sicht entwickelt?

Historische Performance und Vergleiche

C6D0 Aktienübersicht

Belohnungen

Risikoanalyse

Allarity Therapeutics, Inc. Wettbewerber

XTRA:T5O

€2.5m

DB:O7P

€1.3m

MUN:DBI

€1.1m

XTRA:CNW

€6.5m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial

Allarity Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10 million.

Allarity Therapeutics, Inc. Announces Early Discontinuation of Its Phase 2 Clinical Trial of Stenoparib

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer

Recent updates

Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial

Allarity Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10 million.

Allarity Therapeutics, Inc. Announces Early Discontinuation of Its Phase 2 Clinical Trial of Stenoparib

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer

Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)

Allarity Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $0.947 million.

Allarity Therapeutics, Inc. announced that it has received $0.6 million in funding

Allarity Therapeutics, Inc. announced that it has received $0.8 million in funding from 3i, LP

Allarity Therapeutics, Inc. Announces Resignation of James G. Cullem as Member of the Board

Allarity Therapeutics Announces Executive Changes

Allarity Therapeutics, Inc. Announces Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP Companion Diagnostic

Allarity Therapeutics, Inc. Receives A Letter from Nasdaq Listing Qualifications Staff

Allarity Therapeutics Receives Notification from the Nasdaq Listing Qualifications Staff Regarding Non-Compliance with Listing Rule 5550(a)(2)

Allarity Therapeutics Announces Positive Early Data from an Ongoing Clinical Trial, and External Partnering for Its DRP Technology

Allarity Therapeutics, Inc. Announces the Publication of its Clinical Validation of a Novel Drug-Specific DRP-Companion Diagnostic (CDx) for Dovitinib in the Peer-Reviewed Journal PLOS ONE

Allarity Therapeutics, Inc. Announces Board Changes

Allarity Therapeutics, Inc. and Detsamma Investments Pty. Ltd. Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics

Allarity Therapeutics, Inc. Provides Nasdaq Compliance Update

Allarity Therapeutics, Inc. Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives

Allarity Therapeutics, Inc. Announces Initial Results from Its European Phase 2 Clinical Trial Evaluating the Efficacy of Ixempra®? in Metastatic Breast Cancer Patients

Allarity Therapeutics, Inc. announced that it expects to receive $0.35 million in funding from 3i, LP

Allarity Therapeutics Announces Reverse Stock Split of Common Stock to Bring it into Compliance with Nasdaq’s Listing Requirement Regarding Minimum Share Price

Allarity Therapeutics, Inc. Announces Results of Prospective Phase 2 Clinical Study

Allarity Therapeutics Announces Update on Delisting from The Nasdaq Stock Market

Allarity Therapeutics, Inc. Announces Board Changes

Allarity Therapeutics Receives A Written Notice from Nasdaq Regarding Minimum Market Value of Publicly Held Shares

High number of new and inexperienced directors

Allarity Therapeutics Receives Notice from the Nasdaq

Allarity Therapeutics Regains Compliance with NASDAQ Listing Requirements

Allarity Therapeutics, Inc. Announces the Appointment of Jerry Mclaughlin as a Member of its Board of Directors, Effective October 1, 2022

Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Allarity Therapeutics, Inc., Annual General Meeting, Nov 04, 2022

Allarity Therapeutics, Inc. announced delayed 10-Q filing

Allarity Therapeutics Announces Appointment of New Members to Its Board of Directors

Allarity Therapeutics, Inc. Announces Executive Leadership Transition

Allarity Therapeutics, Inc. Appoints Roberto Pili as Member of the Company’s Scientific Advisory Board

Allarity Therapeutics, Inc. Announces Impairment for the First Quarter Ended March 31, 2022

Allarity Therapeutics, Inc. announced delayed 10-Q filing

Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Allarity Therapeutics, Inc. announced delayed annual 10-K filing

Allarity Therapeutics, Inc. Receives Refusal to File Letters from U.S. FDA

Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC)

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

Allarity Therapeutics, Inc.'s Grundlagenzusammenfassung

0.0x

-0.2x

Erträge &amp; Einnahmen

Erträge & Einnahmen